TNO155; 1801765-04-7; batoprotafib; FPJWORQEGI; TNO-155; SHP2 inhibitor TNO155; PTPN11 inhibitor TNO155; (3S,4S)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine; (3S,4S)-8-[6-Amino-5-[(2-amino-3-chloro-4-pyridinyl)thio]-2-pyrazinyl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine; (3S,4S)-8-(6-Amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine; (3S,4S)-8-{6-amino-5-[(2-amino-3-chloropyridin-4-yl)sulfanyl]pyrazin-2-yl}-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine; (3S,4S)-8-(6-Amino-5-((2-amino-3-chloropyridin-4-yl)sulfanyl)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro(4.5)decan-4-amine; Batoprotafib [INN]; UNII-FPJWORQEGI; Tno 155; CHEMBL4650521; SCHEMBL16914359; TNO 155 [WHO-DD]; GTPL12068; BCP33299; EX-A3645; TNO-155; TNO 155; BDBM50553783; MFCD32693919; NSC825523; s8987; compound 1 [PMID: 32910655]; NSC-825523; AC-36494; HY-136173; CS-0120271; D81634; (3S,4S)-8-(6-Amino-5-(2-amino-3-chloropyridin-4-ylthio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine; (3S,4S)-8-{6-amino-5-[(2-amino-3-chloropyridin-4- yl)sulfanyl]pyrazin-2-yl}-3-methyl-2-oxa-8- azaspiro[4.5]decan-4-amine; 2-Oxa-8-azaspiro[4.5]decan-4-amine, 8-[6-amino-5-[(2-amino-3-chloro-4-pyridinyl)thio]-2-pyrazinyl]-3-methyl-, (3S,4S)-; VKS